Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 163

Sort by

Sort Order Select

Journal Articles

Safety and Financial Analysis of Outpatient Hypercvad Arm a Administration for Acute Lymphoblastic Leukemia

Yujiao Sun, Ariel Denson, Katherine Tobon, Rebecca Jean Nelson, Amber Lubas, Bijal D. Shah, Timothy Kubal, Christopher Rodriguez Salamanca, Jad Chahoud, Javier Pinilla-Ibarz, Leidy Lismeris Isenalumhe

Blood (2023) 142 (Supplement 1): 2343.

https://doi.org/10.1182/blood-2023-187050

Published: 2023

Journal Articles

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Blood (2023) 142 (Supplement 1): 7420.

https://doi.org/10.1182/blood-2023-179963

Published: 2023

Journal Articles

A Retrospective Study on Outcomes of Secondary CNS Lymphoma: Pattern of Relapse, Prognostic Factors, and Role of Consolidation Therapy

Aditi Saha, Junmin Whiting, Mohammad Ammad-ud-din, Cole Powell, Kristen Flores, Felix Sanjay, Humaira Sarfraz, Khushali Jhaveri, Michael V. Jaglal, Katherine Tobon, Hayder Saeed, Celeste M. Bello, Bijal D. Shah, Leidy Lismeris Isenalumhe, Javier Pinilla-Ibarz, Lubomir Sokol, Julio C Chavez, Ning Dong

Blood (2023) 142 (Supplement 1): 1750.

https://doi.org/10.1182/blood-2023-188211

Published: 2023

Journal Articles

B-Cell Maturation Antigen (BCMA) Expression and Clinical Features of Plasmablastic Lymphoma (PBL)

Ning Dong, Hailing Zhang, Jinming Song, Jamila Mammadova, Bijal D. Shah, Hayder Saeed, Ariel F. Grajales-Cruz, Leidy Lismeris Isenalumhe, Sameh Gaballa, Celeste M. Bello, Lubomir Sokol, Javier Pinilla-Ibarz, Julio C Chavez

Blood (2023) 142 (Supplement 1): 3138.

https://doi.org/10.1182/blood-2023-184779

Published: 2023

Journal Articles

Trial in Progress: A Phase 1b Study of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Nitin Jain, James D'Olimpio, Andew gillis-Smith, Seung Tae Lee, Nirav N. Shah, Javier Pinilla-Ibarz, Catherine C. Coombs, Jacqueline C. Barrientos, Shuo Ma, Masaaki Sawa, Kyoko Miyamoto, Akinori Arimura, Varsha Gandhi, William G. Wierda

Blood (2023) 142 (Supplement 1): 3288.

https://doi.org/10.1182/blood-2023-182568

Published: 2023

Journal Articles

HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice

Blood (2023) 142 (Supplement 1): 7434.

https://doi.org/10.1182/blood-2023-188683

Published: 2023

Journal Articles

Overall Survival Following First and Second Relapse of DLBCL Treated with Therapies Including Autologous Transplant and CAR-T Cells: Results from the Lion Prospective Observational Registry

Greg Kirkpatrick, Jeffrey M. Switchenko, Melissa Kives, Katelin Baird, Kami J. Maddocks, Jason T. Romancik, Deborah M. Stephens, Harsh Shah, Javier Pinilla-Ibarz, Julio C Chavez, Matthew Matasar, Craig A. Portell, Michelle Churchman, Jonathon B. Cohen, Umar Farooq, Brian K. Link

Blood (2023) 142 (Supplement 1): 6325.

https://doi.org/10.1182/blood-2023-187198

Published: 2023

Journal Articles

Clinical Characteristics, Treatment Strategies, and Outcomes for CLL Patients with BTK Mutation; A Single Center Study

Mohammad Ammad Ud Din, Todd C Knepper, Julio C. Chavez, Lisa Nodzon, Hayder Saeed, Sameh Gaballa, Lubomir Sokol, Ning Dong, Leidy Lismeris Isenalumhe, Celeste M. Bello, Bijal D. Shah, Javier Pinilla-Ibarz

Blood (2023) 142 (Supplement 1): 1911.

https://doi.org/10.1182/blood-2023-179658

Published: 2023

Journal Articles

Comparing Survival Outcomes of Autologous and Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed/Refractory Nodal Peripheral T-Cell Lymphoma

Yumeng Zhang, Jennifer Eatrides, Ashley Rose, Ling Zhang, Farhad Khimani, Aleksandr Lazaryan, Bijal D. Shah, Hayder Saeed, Michael D. Jain, Hien D. Liu, Frederick L. Locke, Javier Pinilla Ibarz, Jongphil Kim, Mohamed A. Kharfan-Dabaja, Ernesto Ayala, Lubomir Sokol, Taiga Nishihori

Blood (2022) 140 (Supplement 1): 10634–10636.

https://doi.org/10.1182/blood-2022-169200

Published: 2022

Journal Articles

Preliminary Results of Voice (Virtual Opinions poll Independent Centered on CLL patients’ Experience): A Global Survey to Assess the Disease-Specific Knowledge and Perspectives of Real-World Patients with CLL

Constantine S. Tam, Javier Pinilla Ibarz, Volkan Karakus, Catherine Moura, Miguel Arturo Pavlovsky, Fernando Nicolás Piotrowsky, Martin Šimkovič, Andrew Smith, Stephan Stilgenbauer

Blood (2022) 140 (Supplement 1): 7933–7935.

https://doi.org/10.1182/blood-2022-166561

Published: 2022

Journal Articles

Risks and Outcomes of Hospitalization in Patients with Chronic Lymphocytic Leukemia Admitted with Immune Thrombocytopenia: An Analysis of the National Inpatient Sample Database (2005-2019)

Mohammad Ammad Ud Din, Hania Liaqat, Javier Pinilla Ibarz, Michael Jaglal

Blood (2022) 140 (Supplement 1): 12384–12385.

https://doi.org/10.1182/blood-2022-165194

Published: 2022

Journal Articles

Targeting Inflammatory Pathways to Reverse Immunosuppressive Tumor Microenvironment in Chronic Lymphocytic Leukemia

Angimar Uriepero, Melanie Mediavilla-Varela, Kamira Maharaj, Wael Gamal, Maria Elena Marquez, John J. Powers, Vishaal Kunta, Eva Sahakian, Pablo Oppezzo, Javier Pinilla Ibarz

Blood (2022) 140 (Supplement 1): 6988–6989.

https://doi.org/10.1182/blood-2022-167331

Published: 2022

Journal Articles

Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study

Ehab L. Atallah, Alexis Visotcky, Kathryn E Flynn, Mei-Jie Zhang, Jerald P. Radich, Jay Yang, Vivian G. Oehler, Srinivas K. Tantravahi, B. Douglas Douglas Smith, Javier Pinilla Ibarz, Kendra Sweet, Michael Mauro, Brian J. Druker, James E. Thompson, Sonia Maldonado-Schmidt, Arielle Baim, Charles A. Schiffer, Vamsi K. Kota, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 3885–3886.

https://doi.org/10.1182/blood-2022-160172

Published: 2022

Journal Articles

Efficacy of Combinatorial Treatment Approaches in CTCL

Melanie Mediavilla-Varela, Eva Sahakian, Carly Harro, John J. Powers, Jose Conejo-Garcia, Lubomir Sokol, Javier Pinilla Ibarz

Blood (2022) 140 (Supplement 1): 11880–11881.

https://doi.org/10.1182/blood-2022-169915

Published: 2022

Journal Articles

Autologous Hematopoietic Cell Transplant Consolidation for First Response Is Associated with Longer Survival in Patients with Nodal Peripheral T-Cell Lymphoma

Yumeng Zhang, Ashley Rose, Jennifer Eatrides, Hayder Saeed, Bijal D. Shah, Aleksandr Lazaryan, Farhad Khimani, Javier Pinilla Ibarz, Hien D. Liu, Frederick L. Locke, Michael D. Jain, Mohamed A. Kharfan-Dabaja, Jongphil Kim, Ling Zhang, Ernesto Ayala, Taiga Nishihori, Lubomir Sokol

Blood (2022) 140 (Supplement 1): 6569–6570.

https://doi.org/10.1182/blood-2022-168347

Published: 2022

Journal Articles

Interim Results of a Prospective Trial Testing Vaccination Against Pneumococcus before and after CD19 CAR T Cell Therapy to Optimize Humoral Immunity

Dasom Lee, Abida Poovathukaran Babu, Salvatore A. Corallo, Meghan A. Menges, Melanie J. Hidalgo-Vargas, Danielle M. Ames, Aleksandr Lazaryan, Taiga Nishihori, Farhad Khimani, Sameh Gaballa, Bijal D. Shah, Javier Pinilla Ibarz, Julio C. Chavez, Michael D. Jain, Frederick L. Locke

Blood (2022) 140 (Supplement 1): 4595–4597.

https://doi.org/10.1182/blood-2022-165776

Published: 2022

Journal Articles

Baseline CRP and Ferritin Identify Patients at High Risk of Poor Outcomes after Axicabtagene Ciloleucel Despite Corticosteroid Prophylaxis

Blood (2022) 140 (Supplement 1): 4678–4680.

https://doi.org/10.1182/blood-2022-171084

Published: 2022

Journal Articles

ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Matthew S. Davids, Saad S. Kenderian, Ian W. Flinn, Brian T. Hill, Michael Maris, Paolo Ghia, Michael Byrne, Nancy L. Bartlett, John M. Pagel, Yan Zheng, Justyna Kanska, Wangshu Zhang, Behzad Kharabi Masouleh, Enrique Granados, Javier Pinilla Ibarz

Blood (2022) 140 (Supplement 1): 7454–7456.

https://doi.org/10.1182/blood-2022-167868

Published: 2022

Journal Articles

Metabolic Abnormalities Associated with T-Cell Exhaustion in CLL Eµ-TCL1 Murine Model

Wael Gamal, Melanie Mediavilla-Varela, Kamira Maharaj, Angimar Uriepero, Vishaal Kunta, Eva Sahakian, Javier Pinilla Ibarz

Blood (2022) 140 (Supplement 1): 6994–6995.

https://doi.org/10.1182/blood-2022-166704

Published: 2022

Journal Articles

A Phase1/1b Dose Escalation/Dose Expansion Study of Prgn-3007 Ultracar-T Cells in Patients with Advanced Hematologic and Solid Tumor Malignancies

Javier Pinilla Ibarz, Amy Lankford, Helen Sabzevari, Bijal D. Shah, Hatem Soliman, Julio C. Chavez, Rutul R Shah

Blood (2022) 140 (Supplement 1): 7486–7487.

https://doi.org/10.1182/blood-2022-168932

Published: 2022

NARROW

Safety and Financial Analysis of Outpatient Hypercvad Arm a Administration for Acute Lymphoblastic Leukemia

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

A Retrospective Study on Outcomes of Secondary CNS Lymphoma: Pattern of Relapse, Prognostic Factors, and Role of Consolidation Therapy

B-Cell Maturation Antigen (BCMA) Expression and Clinical Features of Plasmablastic Lymphoma (PBL)

Trial in Progress: A Phase 1b Study of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice

Overall Survival Following First and Second Relapse of DLBCL Treated with Therapies Including Autologous Transplant and CAR-T Cells: Results from the Lion Prospective Observational Registry

Clinical Characteristics, Treatment Strategies, and Outcomes for CLL Patients with BTK Mutation; A Single Center Study

Comparing Survival Outcomes of Autologous and Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed/Refractory Nodal Peripheral T-Cell Lymphoma

Preliminary Results of Voice (Virtual Opinions poll Independent Centered on CLL patients’ Experience): A Global Survey to Assess the Disease-Specific Knowledge and Perspectives of Real-World Patients with CLL

Risks and Outcomes of Hospitalization in Patients with Chronic Lymphocytic Leukemia Admitted with Immune Thrombocytopenia: An Analysis of the National Inpatient Sample Database (2005-2019)

Targeting Inflammatory Pathways to Reverse Immunosuppressive Tumor Microenvironment in Chronic Lymphocytic Leukemia

Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study

Efficacy of Combinatorial Treatment Approaches in CTCL

Autologous Hematopoietic Cell Transplant Consolidation for First Response Is Associated with Longer Survival in Patients with Nodal Peripheral T-Cell Lymphoma

Interim Results of a Prospective Trial Testing Vaccination Against Pneumococcus before and after CD19 CAR T Cell Therapy to Optimize Humoral Immunity

Baseline CRP and Ferritin Identify Patients at High Risk of Poor Outcomes after Axicabtagene Ciloleucel Despite Corticosteroid Prophylaxis

ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Metabolic Abnormalities Associated with T-Cell Exhaustion in CLL Eµ-TCL1 Murine Model

A Phase1/1b Dose Escalation/Dose Expansion Study of Prgn-3007 Ultracar-T Cells in Patients with Advanced Hematologic and Solid Tumor Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only